The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Janssen Research & Development
Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.
 
Maneesha Mehra
Employment - Janssen
 
Martin Vogel
Employment - Janssen Scientific Affairs
 
Satish Valluri
Employment - Janssen
 
Sandhya Nair
Employment - Janssen
 
Jordan Schecter
No Relationships to Disclose
 
Sundar Jagannath
Honoraria - Celgene; Karyopharm Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Novartis
Research Funding - Bristol-Myers Squibb (Inst); celgene (Inst); Karyopharm Therapeutics (Inst)
 
Katja Weisel
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Research Funding - Amgen; Celgene; Janssen; Sanofi
 
Saad Zafar Usmani
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Seagen; Skyline Diagnostics; Takeda
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen Oncology; Pharmacyclics; Sanofi; Seagen